


BERRAK HÜCRELİ TİP BÖBREK HÜCRELİ KARSİNOMLARDA POTANSİYEL PROGNOSTİK FAKTÖRLERİN VE SAĞKALIM VERİLERİNİN ANALİZİ


Ebru TAŞTEKİN, Fulya ÖZ PUYAN, Hakan AKDERE, Vuslat YÜRÜT-ÇALOĞLU,
Necdet SÜT, Nuray CAN, Filiz ÖZYILMAZ
TRAKYA ÜNİVERSİTESİ TIP FAKÜLTESİ

BÖBREK HÜCRELİ TÜMÖRLER




BERRAK HÜCRELİ TİP BHK

BHBHK larda sıklıkla Von Hippel-Lindau gen mutasyonu




Hipoksi ile indüklenen faktörler (HIF) ve onların hedeflendiği genler

Biz çalışmamızda BHBK'larda HIF-1 α , HIF-2 α , vasküler endotelial büyüme faktörü (VEGF), p53 pozitifliği, mikrodamar yoğunluğu (MDY) ve Ki-67 oranları ile sağ kalım oranları ve prognostik histopatolojik faktörlerin ilişkisini araştırmayı amaçladık.



ÇALIŞMA PLANI



2000-2012
BHBHK

72



Klinik bilgiler
Üroloji- Onkoloji




Histopatolojik bulgular
İmmünohistokimyasal çalışma
Değerlendirme




Verilerin toplanması


MATERYAL & METOD



- HISTOLOJİK DERECE: Fuhrman dereceleme



- EVRE: AJCC 7th ed.



- SARKOMATOİD DİFERANSİYASYON

VEGF DEĞERLENDİRME

0

<%25

1


%26-50

2




>%50

3

YAYGINLIK



VEGF DEĞERLENDİRME



YOĞUNLUK

VEGF SKORLAMA

YAYGINLIK + YOĞUNLUK= Boyanma skoru
(0-6)

0 : Negatif

1-2 : Hafif

3 : Orta

4-6 : Kuvvetli

GRUP 1 (Skor 0-3)

GRUP 2 (Skor 4-6)

HIF-1 ve HIF-2 DEĞERLENDİRME

0

<%25

1

%26-50

2


%51-75

3




>%76-100

4

YAYGINLIK



HIF-1 ve HIF-2 DEĞERLENDİRME



YOĞUNLUK



HIF SKORLAMA


YAYGINLIK + YOĞUNLUK
(0-7)

NEGATİF (Skor <2)


POZİTİF (Skor >2)

P53 ve Ki 67





İSTATİSTİKSEL YÖNTEM



İHK
belirteçler

Fuhrman
Evre
SD

Point Biseral
Korelasyon

Sağkalım
analizleri

Kaplan Meier
ve Log-Rank

Ki 67 ve MDY
Cut Off

ROC Curve

SONUÇLAR

Tablo 1. Hastaların klinik ve patolojik özellikleri

	Hayatta	Hayatta değil	P
Yaş (yıl±SD)	58.48±8.1	65.94±8.6	<0.001*
Cinsiyet	(n/%)	(n/%)	
Erkek	27 (%68)	22 (%69)	0.910
Kadın	13 (% 32)	10 (%31)	
Fuhrman Derecelendirme	(n/%)	(n/%)	
1	5 (%13)	0 (%0)	<0.001*
2	25 (%62)	5 (%16)	
3	10 (%25)	17 (%53)	
4	0 (%0)	10 (%31)	
Evre	(n/%)	(n/%)	
1	20 (%50)	5 (%16)	<0.001*
2	10 (%25)	7 (%22)	
3	10 (%25)	11 (%34)	
4	0 (%0)	9 (%28)	
SD	(n/%)	(n/%)	
+	0 (% 0)	11 (%34)	<0.001*
-	40 (%100)	21 (%66)	

SONUÇLAR


Tablo 2. Hastaların sağ kalım durumlarına göre immunohistokimyasal dağılımı

	Hayatta	Hayatta değil	p
VEGF	(n/%)	(n/%)	
0-3	27 (%68)	7 (%22)	0.002*
4-6	13 (%32)	25 (%78)	
HIF 1 alpha	(n/%)	(n/%)	
+	7 (%18)	15 (%47)	0.007*
-	33 (%82)	17 (%53)	
HIF 2 alpha	(n/%)	(n/%)	
+	5 (%13)	7 (%22)	0.289
-	35 (%87)	25 (%78)	
P53	(n/%)	(n/%)	
+	1 (%3)	5 (%13)	0.041*
-	39 (%87)	27 (%87)	
Ki 67 (median/min-max)	70.5(10-289)	145.5 (27-453)	<0.001*
MVD (median/min-max)	141.5 (91-400)	280 (98-250)	<0.001*


SONUÇLAR


	Prognostic factor		
	Pathological characteristic	r	p
VEGF	Fuhrman	0.692	<0.001*
	Evre	0.935	<0.001*
	SD	0.394	<0.001*
HIF-1 alpha	Fuhrman	0.264	<0.05*
	Evre	0.277	<0.05*
	SD	0.137	>0.05
HIF-2 alpha	Fuhrman	0.073	>0.05
	Evre	0.043	>0.05
	SD	0.086	>0.05
p53	Fuhrman	0.263	<0.05*
	Evre	0.086	>0.05
	SD	0.290	<0.05*
Ki67	Fuhrman	0.644	<0.001*
	Evre	0.738	<0.001*
	SD	0.349	<0.01*
MVD	Fuhrman	0.652	<0.001*
	Evre	0.640	<0.001*

VEGF




HIF 1 α






Ki-67 : 132/1000 (%13.2)
MDY : 182/1000 (%18.2)

SONUÇ



SONUÇ



SUCCESS



Teşekkür ederim...